Bond advises Xeltis on a financing by the European Investment Bank (EIB)

Xeltis will use the funding to accelerate the clinical programs of three applications that could have a significant impact on cardiovascular medicine. The financing is supported by the European Guarantee Fund (EGF), which is part of the EUR 540 billion rescue package in response to the COVID-19 pandemic.

Xeltis is a Swiss-Dutch medical technology company based in Eindhoven. Xeltis is a pioneer in restorative approaches to heart valve replacement and vascular therapies to overcome the limitations of existing options. The so-called endogenous tissue restoration (ETR), created by Xeltis, harnasses body’s natural healing process to facilitate the repair of heart valves and blood vessels with the patient’s own tissue. This technique is based on the revolutionary supramolecular polymer materials, co-invented by Professor Jean-Marie Lehn (who received a Nobel Prize for this technology in 1987) and is owned by Xeltis. Xeltis is currently the most advanced regenerative cardiovascular platform based on polymer technology with several products in the clinical phase.

In addition to Bond and Venture Lawyers, the Swiss law firm Wenger Vieli in Zurich acted for Xeltis. EIB was assisted by the Amsterdam and Zurich offices of Loyens & Loeff.

For more information, see: https://xeltis.com/xeltis-lands-e15-million-european-financing-from-eib/.